001     276276
005     20250209000733.0
024 7 _ |a 10.1016/j.tjpad.2024.100030
|2 doi
024 7 _ |a pmid:39863323
|2 pmid
024 7 _ |a 2274-5807
|2 ISSN
024 7 _ |a 2426-0266
|2 ISSN
024 7 _ |a altmetric:173682023
|2 altmetric
037 _ _ |a DZNE-2025-00255
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Grazia, Alice
|0 P:(DE-2719)9001307
|b 0
|u dzne
245 _ _ |a Basal forebrain global functional connectivity is preserved in asymptomatic presenilin-1 E280A mutation carriers: Results from the Colombia cohort.
260 _ _ |a Cham
|c 2025
|b Springer International Publishing
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1738670146_16422
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Imaging studies showed early atrophy of the cholinergic basal forebrain in prodromal sporadic Alzheimer's disease and reduced posterior basal forebrain functional connectivity in amyloid positive individuals with subjective cognitive decline. Similar investigations in familial cases of Alzheimer's disease are still lacking.To test whether presenilin-1 E280A mutation carriers have reduced basal forebrain functional connectivity and whether this is linked to amyloid pathology.This is a cross-sectional study that analyzes baseline functional imaging data.We obtained data from the Colombia cohort Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial.We analyzed data from 215 asymptomatic subjects carrying the presenilin-1 E280A mutation [64% female; 147 carriers (M = 35 years), 68 noncarriers (M = 40 years)].We extracted functional magnetic resonance imaging data using seed-based connectivity analysis to examine the anterior and posterior subdivisions of the basal forebrain. Subsequently, we performed a Bayesian Analysis of Covariance to assess the impact of carrier status on functional connectivity in relation to amyloid positivity. For comparison, we also investigated hippocampus connectivity.We found no effect of carrier status on anterior (Bayesian Factor10 = 1.167) and posterior basal forebrain connectivity (Bayesian Factor10 = 0.033). In carriers, we found no association of amyloid positivity with basal forebrain connectivity.We falsified the hypothesis of basal forebrain connectivity reduction in preclinical mutation carriers with amyloid pathology. If replicated, these findings may not only confirm a discrepancy between familial and sporadic Alzheimer's disease, but also suggest new potential targets for future treatments.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Basal forebrain
|2 Other
650 _ 7 |a Bayesian analysis
|2 Other
650 _ 7 |a Colombia cohort
|2 Other
650 _ 7 |a PSEN1 E280A
|2 Other
650 _ 7 |a Resting-state fMRI
|2 Other
650 _ 7 |a Presenilin-1
|2 NLM Chemicals
650 _ 7 |a PSEN1 protein, human
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Presenilin-1: genetics
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Colombia
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Cross-Sectional Studies
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging
|2 MeSH
650 _ 2 |a Mutation
|2 MeSH
650 _ 2 |a Basal Forebrain: diagnostic imaging
|2 MeSH
650 _ 2 |a Alzheimer Disease: genetics
|2 MeSH
650 _ 2 |a Alzheimer Disease: diagnostic imaging
|2 MeSH
650 _ 2 |a Alzheimer Disease: physiopathology
|2 MeSH
650 _ 2 |a Heterozygote
|2 MeSH
650 _ 2 |a Cohort Studies
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
700 1 _ |a Dyrba, Martin
|0 P:(DE-2719)2810283
|b 1
|u dzne
700 1 _ |a Pomara, Nunzio
|b 2
700 1 _ |a Temp, Anna G
|0 P:(DE-2719)2814291
|b 3
700 1 _ |a Grothe, Michel J
|0 P:(DE-2719)2810708
|b 4
700 1 _ |a Teipel, Stefan J
|0 P:(DE-2719)2000026
|b 5
|e Last author
|u dzne
700 1 _ |a Initiative, Alzheimer's Prevention
|b 6
|e Collaboration Author
773 _ _ |a 10.1016/j.tjpad.2024.100030
|g Vol. 12, no. 2, p. 100030 -
|0 PERI:(DE-600)2782183-3
|n 2
|p 100030
|t The journal of prevention of Alzheimer's disease
|v 12
|y 2025
|x 2274-5807
856 4 _ |u https://pub.dzne.de/record/276276/files/DZNE-2025-00255%20SUP.zip
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/276276/files/DZNE-2025-00255.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/276276/files/DZNE-2025-00255.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:276276
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 0
|6 P:(DE-2719)9001307
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2810283
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2000026
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-05
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b JPAD-J PREV ALZHEIM : 2022
|d 2024-12-05
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-05
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-05
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-05
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b JPAD-J PREV ALZHEIM : 2022
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-05
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research (Rostock /Greifswald)
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1510100
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21